Reify Health vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Reify Health raised $220M Series D at $4.8B valuation; OneStudyTeam and Care Access accelerate clinical trial site operations and decentralized enrollment; $407M total raised to bridge diversity gap in trials.
About
Reify Health is a clinical trial acceleration company whose two platform arms — OneStudyTeam and Care Access — address the two biggest friction points in clinical research: site operations efficiency and patient enrollment reach. OneStudyTeam provides workflow software that automates the administrative burden on clinical research sites, enabling faster startup, better sponsor-site collaboration, and compliant data capture throughout trial execution. Care Access operates a decentralized clinical trial infrastructure that brings research directly to patients in underserved communities, expanding the diversity and geographic reach of clinical study populations.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.